Endometrial sampling: when? where? why? with what?

JT CHAMBERS, SK CHAMBERS - Clinical obstetrics and …, 1992 - journals.lww.com
Abnormal vaginal bleeding is a common problem accounting for up to 20% of office visits to
a general gynecologist." With greater acceptance of the benefits from hormonal replacement …

NRF2 controls iron homeostasis and ferroptosis through HERC2 and VAMP8

A Anandhan, M Dodson, A Shakya, J Chen, P Liu… - Science …, 2023 - science.org
Enhancing the intracellular labile iron pool (LIP) represents a powerful, yet untapped
strategy for driving ferroptotic death of cancer cells. Here, we show that NRF2 maintains iron …

[PDF][PDF] Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal …

AN Fader, DM Roque, E Siegel… - Journal of Clinical …, 2018 - clf1.medpagetoday.com
Purpose Uterine serous carcinoma is a rare, aggressive variant of endometrial cancer.
Trastuzumab is a humanized monoclonal antibody that targets human epidermal growth …

BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

KK Lin, MI Harrell, AM Oza, A Oaknin, I Ray-Coquard… - Cancer discovery, 2019 - AACR
A key resistance mechanism to platinum-based chemotherapies and PARP inhibitors in
BRCA-mutant cancers is the acquisition of BRCA reversion mutations that restore protein …

[HTML][HTML] Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)

EM Swisher, TT Kwan, AM Oza, AV Tinker… - Nature …, 2021 - nature.com
Abstract ARIEL2 (NCT01891344) is a single-arm, open-label phase 2 study of the PARP
inhibitor (PARPi) rucaparib in relapsed high-grade ovarian carcinoma. In this post hoc …

Role of CSF-1 in progression of epithelial ovarian cancer

SK Chambers - Future oncology, 2009 - Future Medicine
Despite the dismal outcome seen in the majority of epithelial ovarian cancer patients, there
is ongoing progress in understanding the disease at a molecular level. Elucidation of …

[PDF][PDF] Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer.

BY Karlan, AM Oza, GE Richardson, DM Provencher… - J Clin …, 2010 - researchgate.net
Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With
Weekly Paclitaxel in Patients With Recurren Page 1 Randomized, Double-Blind, Placebo-Controlled …

[HTML][HTML] Tubal origin of 'ovarian'low-grade serous carcinoma

J Li, N Abushahin, S Pang, L Xiang, SK Chambers… - Modern Pathology, 2011 - Elsevier
Ovarian low-grade serous carcinomas are thought to evolve in a stepwise fashion from
ovarian epithelial inclusions, cystadenomas, and borderline tumors. The current study was …

Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a …

SK Chambers, BM Kacinski, CM Ivins… - Clinical cancer research …, 1997 - AACR
Markedly elevated levels of macrophage colony-stimulating factor (CSF-1) in the serum and
ascites of epithelial ovarian cancer patients have been previously associated with a poor …

A phase III study of pafolacianine injection (OTL38) for intraoperative imaging of folate receptor–positive ovarian cancer (Study 006)

JL Tanyi, LM Randall, SK Chambers… - Obstetrical & …, 2023 - journals.lww.com
Complete resection of macroscopic disease remains a key focus of cytoreductive surgery for
the treatment of ovarian cancer. Barriers to achieving complete resection include small-sized …